CO2023014681A2 - Composiciones y métodos para inhibir la expresión del componente 3 del complemento - Google Patents
Composiciones y métodos para inhibir la expresión del componente 3 del complementoInfo
- Publication number
- CO2023014681A2 CO2023014681A2 CONC2023/0014681A CO2023014681A CO2023014681A2 CO 2023014681 A2 CO2023014681 A2 CO 2023014681A2 CO 2023014681 A CO2023014681 A CO 2023014681A CO 2023014681 A2 CO2023014681 A2 CO 2023014681A2
- Authority
- CO
- Colombia
- Prior art keywords
- expression
- methods
- complement component
- inhibiting
- compositions
- Prior art date
Links
- 102000016918 Complement C3 Human genes 0.000 title abstract 2
- 108010028780 Complement C3 Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 108091030071 RNAI Proteins 0.000 abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000003831 deregulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177254P | 2021-04-20 | 2021-04-20 | |
| PCT/US2022/025648 WO2022226127A1 (en) | 2021-04-20 | 2022-04-20 | Compositions and methods for inhibiting complement component 3 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014681A2 true CO2023014681A2 (es) | 2024-01-25 |
Family
ID=83723122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014681A CO2023014681A2 (es) | 2021-04-20 | 2023-10-30 | Composiciones y métodos para inhibir la expresión del componente 3 del complemento |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| CN118202053A (zh) * | 2023-02-17 | 2024-06-14 | 苏州时安生物技术有限公司 | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 |
| EP4747385A1 (en) * | 2023-07-21 | 2026-05-27 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of complement component 3 (c3) |
| WO2025168134A1 (zh) * | 2024-02-08 | 2025-08-14 | 北京安龙生物医药有限公司 | 靶向补体成分c3基因的寡核苷酸及其用途 |
| CN121592644A (zh) * | 2024-08-16 | 2026-03-03 | 施能康生物医药（苏州）有限公司 | 靶向C3补体的RNAi试剂及其用途 |
| WO2026145589A1 (zh) * | 2025-01-03 | 2026-07-09 | 成都先衍生物技术有限公司 | 一种同时抑制C3与C5基因表达的dsRNA缀合物及其用途 |
| CN121154665B (zh) * | 2025-11-21 | 2026-02-27 | 天津医科大学第二医院 | 尿苷在防治糖尿病肾病药物开发过程中及药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CN101426913A (zh) * | 2005-11-30 | 2009-05-06 | 因特拉迪格姆公司 | 使用siRNA敲减基因表达和改善实体器官和细胞移植的组合物和方法 |
| WO2010033225A2 (en) * | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010042755A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| EP3526328A4 (en) * | 2016-10-17 | 2020-05-27 | Apellis Pharmaceuticals, Inc. | COMBINATION THERAPY FOR C3 INHIBITION |
| CA3078971A1 (en) * | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| CN112368381A (zh) * | 2018-04-18 | 2021-02-12 | 迪克纳制药公司 | 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 |
| WO2020104669A1 (en) * | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| WO2021037941A1 (en) * | 2019-08-27 | 2021-03-04 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| CA3158320A1 (en) * | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| MX2022009870A (es) * | 2020-02-14 | 2022-11-07 | Apellis Pharmaceuticals Inc | Ácidos ribonucleicos (arn) para la inhibición del complemento. |
| CN116761616A (zh) * | 2021-01-22 | 2023-09-15 | 阿耐拉姆制药公司 | 经修饰的双链寡核苷酸 |
| EP4346844A4 (en) * | 2021-05-26 | 2025-09-10 | Apellis Pharmaceuticals Inc | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS |
-
2022
- 2022-04-20 IL IL307721A patent/IL307721A/en unknown
- 2022-04-20 JP JP2023564255A patent/JP2024515344A/ja active Pending
- 2022-04-20 BR BR112023021703A patent/BR112023021703A2/pt unknown
- 2022-04-20 CN CN202280034163.4A patent/CN117295819A/zh active Pending
- 2022-04-20 AU AU2022261922A patent/AU2022261922A1/en active Pending
- 2022-04-20 US US18/287,260 patent/US20250002908A1/en active Pending
- 2022-04-20 MX MX2023012385A patent/MX2023012385A/es unknown
- 2022-04-20 EP EP22792454.5A patent/EP4326876A4/en active Pending
- 2022-04-20 KR KR1020237036421A patent/KR20230173116A/ko active Pending
- 2022-04-20 CA CA3177629A patent/CA3177629A1/en active Pending
- 2022-04-20 WO PCT/US2022/025648 patent/WO2022226127A1/en not_active Ceased
-
2023
- 2023-10-30 CO CONC2023/0014681A patent/CO2023014681A2/es unknown
-
2025
- 2025-04-15 JP JP2025066627A patent/JP2025100729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230173116A (ko) | 2023-12-26 |
| JP2025100729A (ja) | 2025-07-03 |
| WO2022226127A1 (en) | 2022-10-27 |
| EP4326876A1 (en) | 2024-02-28 |
| CA3177629A1 (en) | 2022-10-27 |
| IL307721A (en) | 2023-12-01 |
| JP2024515344A (ja) | 2024-04-09 |
| US20250002908A1 (en) | 2025-01-02 |
| AU2022261922A1 (en) | 2023-10-26 |
| CN117295819A (zh) | 2023-12-26 |
| MX2023012385A (es) | 2024-02-07 |
| BR112023021703A2 (pt) | 2024-01-30 |
| EP4326876A4 (en) | 2026-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000140A (es) | Composiciones y métodos para inhibir el factor b del complemento | |
| MX2023012385A (es) | Composiciones y metodos para inhibir la expresion del componente 3 del complemento. | |
| CO2024006046A2 (es) | Composiciones de arni contra el factor b del complemento (cfb) y sus métodos de uso | |
| MX2013011721A (es) | Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| BR112022021136A2 (pt) | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas | |
| CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
| BR112022009216A2 (pt) | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) | |
| MX2024012816A (es) | Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas | |
| UY36671A (es) | COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO | |
| CL2023003984A1 (es) | Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina | |
| CO2025017101A2 (es) | Composiciones y métodos para inhibir la expresión del factor de coagulación xi (fxi) | |
| AR125230A1 (es) | COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO | |
| AR125992A1 (es) | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1) | |
| MX2025015672A (es) | Composiciones y metodos para inhibir la expresion del factor del complemento b (cfb) | |
| MX2026001746A (es) | Sirna, conjugado de sirna, composicion farmaceutica y sus usos | |
| AR128312A1 (es) | Composiciones y métodos para inhibir el factor b del complemento | |
| MX2025014316A (es) | Oligómeros antisentido opa1 para el tratamiento de afecciones y enfermedades | |
| CO2024004737A2 (es) | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 | |
| AR120817A1 (es) | Oligonucleótidos mejorados para inhibir la expresión de scn9a | |
| ECSP24032618A (es) | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 | |
| AR125452A1 (es) | Composiciones de arni contra la serina proteasa transmembrana 6 (tmprss6) y sus métodos de uso | |
| AR112270A1 (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia | |
| AR125021A1 (es) | COMPOSICIONES DE ARNi CONTRA EL GEN SIMILAR A ANGIOPOYETINA 3 (ANGPTL3) Y SUS MÉTODOS DE USO | |
| AR130702A1 (es) | COMPOSICIONES DE iARN DE PLASMINÓGENO (PLG) Y MÉTODOS DE USO DE LAS MISMAS | |
| BR112023026411A2 (pt) | Oligonucleotídeo antisense, composição farmacêutica contendo pelo menos um oligonucleotídeo antisense, método de tratamento de um animal, método de inibição da expressão de efrinab2 e método para restauração da função de nefrina em células ou tecidos |